J Wiegand

1.5k total citations
18 papers, 493 citations indexed

About

J Wiegand is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, J Wiegand has authored 18 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in J Wiegand's work include Hemoglobinopathies and Related Disorders (6 papers), Iron Metabolism and Disorders (6 papers) and Peptidase Inhibition and Analysis (4 papers). J Wiegand is often cited by papers focused on Hemoglobinopathies and Related Disorders (6 papers), Iron Metabolism and Disorders (6 papers) and Peptidase Inhibition and Analysis (4 papers). J Wiegand collaborates with scholars based in United States, Germany and France. J Wiegand's co-authors include G Luchetta, Sajid Khan, Daohong Zhou, Guangrong Zheng, Peiyi Zhang, W. King, Vivekananda Budamagunta, Xuan Zhang, Dinesh Thummuri and Dongwen Lv and has published in prestigious journals such as Blood, Cancer Research and Journal of Hematology & Oncology.

In The Last Decade

J Wiegand

18 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Wiegand United States 11 208 180 150 146 55 18 493
Natalie Le Australia 3 176 0.8× 127 0.7× 66 0.4× 102 0.7× 98 1.8× 3 427
Shaina L. Byrne United States 14 171 0.8× 255 1.4× 159 1.1× 78 0.5× 194 3.5× 19 500
Christophe Henry France 12 160 0.8× 54 0.3× 35 0.2× 158 1.1× 41 0.7× 25 459
E. Cama United States 9 206 1.0× 80 0.4× 24 0.2× 40 0.3× 28 0.5× 9 575
JoLyn Turner United States 7 116 0.6× 59 0.3× 85 0.6× 111 0.8× 36 0.7× 9 390
Saleh M. Abdullah Saudi Arabia 10 113 0.5× 69 0.4× 38 0.3× 48 0.3× 13 0.2× 33 334
ER Huehns United Kingdom 12 92 0.4× 218 1.2× 274 1.8× 58 0.4× 76 1.4× 17 558
Huiyong Chen China 9 91 0.4× 190 1.1× 196 1.3× 29 0.2× 54 1.0× 19 372
Michael R. Downing United States 9 206 1.0× 244 1.4× 53 0.4× 44 0.3× 36 0.7× 14 527
Ulrike Pfaar Switzerland 10 190 0.9× 131 0.7× 89 0.6× 201 1.4× 7 0.1× 12 568

Countries citing papers authored by J Wiegand

Since Specialization
Citations

This map shows the geographic impact of J Wiegand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Wiegand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Wiegand more than expected).

Fields of papers citing papers by J Wiegand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Wiegand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Wiegand. The network helps show where J Wiegand may publish in the future.

Co-authorship network of co-authors of J Wiegand

This figure shows the co-authorship network connecting the top 25 collaborators of J Wiegand. A scholar is included among the top collaborators of J Wiegand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Wiegand. J Wiegand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Khan, Sajid, Lin Cao, J Wiegand, et al.. (2024). PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells. 13(6). 528–528. 14 indexed citations
2.
Khan, Sajid, Patrick Kellish, Nick Connis, et al.. (2023). Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discovery. 9(1). 1–1. 31 indexed citations
3.
Khan, Sajid, J Wiegand, Peiyi Zhang, et al.. (2022). Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers. Cancer Research. 82(12_Supplement). 5313–5313. 1 indexed citations
4.
Thummuri, Dinesh, Sajid Khan, Patrick W. Underwood, et al.. (2021). Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216. Molecular Cancer Therapeutics. 21(1). 184–192. 51 indexed citations
5.
He, Yonghan, Raphael Koch, Vivekananda Budamagunta, et al.. (2020). DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology. 13(1). 95–95. 92 indexed citations
6.
He, Yonghan, Raphael Koch, Vivekananda Budamagunta, et al.. (2019). DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia. Blood. 134(Supplement_1). 303–303. 4 indexed citations
7.
Zhao, Peng, et al.. (2007). Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Therapy. 15(2). 73–84. 10 indexed citations
8.
Bergeron, Raymond J., Ronald L. Merriman, J Wiegand, et al.. (2000). Metabolism and pharmacokinetics of N1,N11-diethylnorspermine in a Cebus apella primate model.. PubMed. 60(16). 4433–9. 8 indexed citations
9.
Bergeron, Raymond J., William R. Weimar, & J Wiegand. (1999). Pharmacokinetics of Orally Administered Desferrithiocin Analogs in Cebus apella Primates. Drug Metabolism and Disposition. 27(12). 1496–1498. 7 indexed citations
10.
Bergeron, Raymond J., William R. Weimar, G Luchetta, Charles A. Sninsky, & J Wiegand. (1996). Metabolism and pharmacokinetics of N1,N14-diethylhomospermine.. Drug Metabolism and Disposition. 24(3). 334–343. 3 indexed citations
11.
Bergeron, Raymond J., et al.. (1995). Metabolism and pharmacokinetics of N1,N11-diethylnorspermine.. Drug Metabolism and Disposition. 23(10). 1117–1125. 22 indexed citations
12.
13.
14.
King, W., et al.. (1993). A comparison of the iron-clearing properties of parabactin and desferrioxamine. Blood. 82(8). 2552–2557. 11 indexed citations
15.
Wiegand, J, et al.. (1992). Synovial and serum levels of triamcinolone following intra‐articular administration of triamcinolone acetonide in the horse*. Journal of Veterinary Pharmacology and Therapeutics. 15(3). 240–246. 30 indexed citations
16.
17.
18.
Försterling, Horst‐Dieter, et al.. (1969). Lichtabsorption von Farbstoff-Molekülpaaren in Sandwichsystemen aus monomolekularen Schichten. Zeitschrift für Naturforschung A. 24(11). 1821–1830. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natalie Le Breakdown of academic impact, for papers by Shaina L. Byrne Breakdown of academic impact, for papers by Christophe Henry Breakdown of academic impact, for papers by E. Cama Breakdown of academic impact, for papers by JoLyn Turner Breakdown of academic impact, for papers by Saleh M. Abdullah Breakdown of academic impact, for papers by ER Huehns Breakdown of academic impact, for papers by Huiyong Chen Breakdown of academic impact, for papers by Michael R. Downing Breakdown of academic impact, for papers by Ulrike Pfaar
Rankless by CCL
2026